Morepen Laboratories Ltd

- Morepen Laboratories is completing the expansion of API manufacturing capacity from 314 KL to 600 KL, nearly doubling capacity, expected to be completed within FY '26. - After the 600 KL capacity expansion, there are no immediate plans for further capacity increases. - The company is exploring partnerships with outsourcing vendors who have surplus capacity or complementary product mixes. - Investment is ongoing in backward integration, especially in the medical devices segment, aiming to increase EBITDA margins. - There is focus on expanding formulations and OTC products, including hiring new teams and launching products in new markets like the U.S. via Amazon. - R&D investments continue with 55 scientists, 168 patents filed, and development of new molecules to drive future growth.

- The company expects overall growth of 10% to 15% at the company level for FY '26 and FY '27. - Finished dosage business has shown a 21% growth in 2 years, with expectations of higher growth than API segment. - API business growth has been muted (~3-4%), but capacity expansion from 314 KL to 600 KL by FY '26 is expected to boost revenues. - Export focus is increasing, with export revenues growing 26% over 3 years; export now constitutes 72% of business. - Medical devices segment is expanding capacity significantly (e.g., BP monitors capacity doubling from 9 to 18 lakh units) and expected to deliver strong growth given health awareness trends. - The new molecule contribution in API is rising, forecasting faster growth in this segment. - Expansion in manpower, particularly medical representatives (from 200 to 1,200 over 3 years), is expected to drive formulation sales growth. - Long-term EBITDA growth is expected, linked to product mix improvements, exports, and capacity increases.

- The company generally does not give formal guidance but indicates expected growth of 10% to 15% at the company level for FY '26 and FY '27. - EBITDA is expected to increase, particularly due to product mix improvements: - API business EBITDA to grow with capacity expansion and increased exports. - Finished dosage (formulations) business has higher margins (around 70%) compared to API (30-40%) and is expected to improve EBITDA, with some investment phase in initial years. - Medical devices segment continues consistent volume growth, boosting EBITDA. - Operating expenses are being tightly controlled amid lower sales realizations. - With capacity expansion (e.g., API capacity doubled to 600 KL expected by FY '26 end) and increased outsourcing partnerships, revenues and margins are projected to improve. - Overall, improvements in revenue, EBITDA, and PAT margins are anticipated through strategic product and market focus.

- The company has 600 KL capacity planned for FY '26, expected to be completed within the year. - Current installed capacity is 514 KL as part of capacity expansion (91% increase targeted). - They are working on building a good outsourcing partner network to manage excess demand or capacity shortage. - Despite a recent price drop of 24%, quantity sold has increased by 57% in APIs, indicating robust order intake. - Some export orders (US and Europe) were deferred last quarter, impacting short-term revenues. - Management is in a "wait and watch" mode regarding price acceptance by Indian customers due to recent raw material price increases and global market conditions. - They are ready to compromise on revenue short term (1-2 months or quarters) but will not go below certain price levels. - Confident that API prices have almost bottomed out, implying a more stable orderbook and pricing environment ahead.

- There is no explicit mention of any current or planned fundraising through debt or equity in the transcript. - The company is focused on organic growth through capacity expansion (e.g., completing 600 KL API capacity by FY '26). - Discussions emphasize revenue growth, margin improvement, and operational efficiencies rather than funding needs. - No comments were made about raising capital to fund these expansions or for any other purposes. - The management's strategy indicates reliance on internal resources, customer partnerships, and outsourcing rather than external fundraising. - No specific plans or intentions to issue new equity or take on additional debt were disclosed during the call.